The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma

INTRODUCTION: Cabozantinib is an oral tyrosine kinase inhibitor that is approved for the treatment of metastatic renal cell carcinoma (mRCC). Cabozantinib is a weak base that exhibits a pH‐dependent solubility profile in vitro which raises concerns about its bioavailability in patients treated with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Rassy, Elie, Cerbone, Luigi, Auclin, Edouard, Benchimoll‐Zouari, Axelle, Flippot, Ronan, Alves Costa Silva, Carolina, Colomba, Emeline, Geraud, Arthur, Guida, Annalisa, Mir, Olivier, Combarel, David, Paci, Angelo, Escudier, Bernard, Albiges, Laurence
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Genitourinary Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100573/
https://ncbi.nlm.nih.gov/pubmed/33554383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13711
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados